698 Results for "

VEGF-R

" in MedChemExpress (MCE) Product Catalog:
Products (698)

698 Results for "VEGF-R" in MCE Product Catalog:

  • Targets Recommended:
  • Recombinant Proteins Recommended:
307
307 Publications Verification
Referencia número: HY-10201
No. CAS: 284461-73-0
Pureza:  99.92%
Synonyms: Bay 43-9006
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
loading...
    loading...
307
307 Publications Verification
Referencia número: HY-10201A
No. CAS: 475207-59-1
Pureza:  99.75%
Synonyms: Bay 43-9006 tosylate
Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
loading...
    loading...
108
108 Cited Publications
Referencia número: HY-10255A
No. CAS: 557795-19-4
Pureza:  99.04%
Synonyms: SU 11248
Áreas de investigación:  

Cancer

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .
loading...
    loading...
108
108 Cited Publications
Referencia número: HY-10255
No. CAS: 341031-54-7
Pureza:  99.86%
Synonyms: SU 11248 Malate
Sunitinib (SU 11248) Malat is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib Malat, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .
loading...
    loading...
108
108 Cited Publications
Referencia número: HY-10255C
No. CAS: 1818285-48-1
Synonyms: SU 11248 glucuronate
Áreas de investigación:  

Cancer

Sunitinib (SU 11248) glucuronate is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib glucuronate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .
loading...
    loading...
101
101 Cited Publications
Referencia número: HY-10981
No. CAS: 417716-92-8
Pureza:  99.75%
Synonyms: E7080
Target:  

VEGFR FGFR PDGFR c-Kit RET

Áreas de investigación:  

Cancer

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
101
101 Cited Publications
Referencia número: HY-10981A
No. CAS: 857890-39-2
Pureza:  99.86%
Synonyms: E7080 mesylate
Target:  

VEGFR FGFR PDGFR RET c-Kit

Áreas de investigación:  

Cancer

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
96
96 Cited Publications
Referencia número: HY-13308
No. CAS: 835621-07-3
Pureza:  99.58%
Synonyms: BAY 73-4506 hydrochloride
Target:  

VEGFR Autophagy PDGFR Raf RET

Áreas de investigación:  

Cancer

Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively .
loading...
    loading...
96
96 Cited Publications
Referencia número: HY-10331
No. CAS: 755037-03-7
Pureza:  99.93%
Synonyms: BAY 73-4506
Áreas de investigación:  

Cancer

Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
loading...
    loading...
96
96 Cited Publications
Referencia número: HY-10331A
No. CAS: 1019206-88-2
Pureza:  99.96%
Synonyms: BAY 73-4506 monohydrate
Áreas de investigación:  

Cancer

Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
loading...
    loading...
79
79 Cited Publications
Referencia número: HY-10374
No. CAS: 204005-46-9
Pureza:  99.96%
Synonyms: SU5416
Target:  

VEGFR

Áreas de investigación:  

Cancer

Semaxinib (SU5416) is a potent and selective inhibitor of VEGFR (Flk-1/KDR) with an IC50 of 1.23 μM .
loading...
    loading...
74
74 Cited Publications
Referencia número: HY-50904
No. CAS: 656247-17-5
Synonyms: BIBF 1120
Target:  

PDGFR VEGFR FGFR

Áreas de investigación:  

Cancer

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
loading...
    loading...
74
74 Cited Publications
Referencia número: HY-11106
No. CAS: 656247-18-6
Pureza:  99.96%
Synonyms: BIBF 1120 esylate
Target:  

PDGFR VEGFR FGFR

Áreas de investigación:  

Cancer

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
loading...
    loading...
58
58 Cited Publications
Referencia número: HY-13016
No. CAS: 849217-68-1
Pureza:  99.96%
Synonyms: XL184; BMS-907351
Áreas de investigación:  

Cancer

Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .
loading...
    loading...
57
57 Cited Publications
Referencia número: HY-12044
No. CAS: 1140909-48-3
Pureza:  99.90%
Synonyms: XL184 S-malate; BMS-907351 S-malate
Target:  

VEGFR Apoptosis

Áreas de investigación:  

Cancer

Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
loading...
    loading...
56
56 Cited Publications
Referencia número: HY-12047
No. CAS: 943319-70-8
Pureza:  99.67%
Synonyms: AP24534
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .
loading...
    loading...
56
56 Cited Publications
Referencia número: HY-108766
No. CAS: 1114544-31-8
Pureza:  99.76%
Synonyms: AP24534 hydrochloride
Áreas de investigación:  

Infection Cancer

Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .
loading...
    loading...
42
42 Cited Publications
Referencia número: HY-10065
No. CAS: 319460-85-0
Pureza:  99.90%
Synonyms: AG-013736
Target:  

VEGFR PDGFR

Áreas de investigación:  

Cancer

Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.
loading...
    loading...
39
39 Cited Publications
Referencia número: HY-10230
No. CAS: 120685-11-2
Pureza:  99.91%
Synonyms: PKC412; CGP 41251
Áreas de investigación:  

Cancer

Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
loading...
    loading...
37
37 Cited Publications
Referencia número: HY-N0135
No. CAS: 568-72-9
Synonyms: Dan Shen ketone
Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2.
loading...
    loading...